Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01932606
Other study ID # 13-004077
Secondary ID
Status Completed
Phase Phase 2
First received August 27, 2013
Last updated February 15, 2016
Start date August 2013
Est. completion date October 2014

Study information

Verified date February 2016
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that has no proven effective treatment. This study assessed the effects of acute nitrite administration on resting and exercise hemodynamics in patients with HFpEF.


Description:

Subjects were studied on their long-term medications in the post-absorptive state and supine position. Right heart catheterization was performed with simultaneous expired gas analysis at rest and during supine exercise at a 20 Watts workload for 5 minutes. After the first exercise phase (before any drug administration) and after return to steady-state baseline hemodynamic values, subjects were randomized. Study drug or placebo was infused for 5 minutes. After a 10 minute observation period, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20 Watts workload for 5 minutes, identical to the study's first phase. Arterial and venous blood samples and hemodynamic and expired gas data were acquired during each stage of the protocol.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Scheduled to undergo a cardiac catheterization procedure.

- Clinical symptoms of shortness of breath and fatigue

- Normal left ventricular ejection fraction (=50%)

- Elevated left ventricular filling pressures at cardiac catheterization (defined as resting pulmonary capillary wedge pressure (PCWP)>15 mmHg and/or PCWP=25 mmHg during exercise)

Exclusion Criteria:

- Systolic BP <120 mmHg

- Prior nitrate therapy (within previous 2 weeks)

- Glucose 6-phosphate dehydrogenase (G6PD) deficiency

- Other "non-HFpEF" specific causes of heart failure such as significant valvular disease (>moderate left-sided regurgitation, >mild stenosis), severe pulmonary disease, unstable coronary disease or coronary spasm, primary renal or hepatic disease, constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Nitrite
Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
Saline Placebo for Nitrite
Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).

Locations

Country Name City State
United States Mayo Clinic in Rochester Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Barry Borlaug

Country where clinical trial is conducted

United States, 

References & Publications (1)

Borlaug BA, Koepp KE, Melenovsky V. Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2015 Oct 13;66(15):1672-82. doi: 10.1016/j.jacc.2015.07.067. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Exercise Pulmonary Capillary Wedge Pressure (PCWP) Pulmonary capillary wedge pressure (PCWP) provides an indirect estimate of left atrial pressure (LAP). PCWP is the pressure measured by wedging a pulmonary catheter with an inflated balloon into a small pulmonary arterial branch. during repeat exercise run, approximately 30 minutes after study drug administration No
Secondary Change in Central Pressures After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in Heart Rate After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in Blood Pressure After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in Pulmonary Vascular Resistance (PVR) After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Pulmonary Vascular Resistance (PVR) is the resistance to flow that must be overcome to push blood through the pulmonary vasculature. Acute and chronic lung disease can both cause an increase in PVR. Chronic PVR can lead to right sided heart failure. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Pulmonary Artery (PA) Compliance After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Pulmonary artery compliance is an index of the elasticity of the blood vessel, an indication of arterial stiffness. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Systemic Vascular Resistance (SVR) After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Systemic vascular resistance (SVR) refers to the resistance to blood flow offered by all of the systemic vasculature, excluding the pulmonary vasculature. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Left Ventricular Stroke Work (LVSW) After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Stroke work refers to the work done by the ventricle to eject a volume of blood (i.e., stroke volume) into the aorta. Ventricular stroke work can be estimated as the product of stroke volume and mean aortic pressure during ejection. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Oxygen Consumption (VO_2) After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in Arteriovenous Oxygen Content Difference After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Arteriovenous oxygen difference is the difference in the oxygen content of the blood between the arterial blood and the venous blood. It is an indication of how much oxygen is removed from the blood in capillaries as the blood circulates in the body. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Cardiac Output After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) The volume of blood pumped per minute by each ventricle of the heart. Cardiac output is equal to the stroke volume (the amount of blood pumped from a ventricle in a single heartbeat) times the heart rate. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Stroke Volume After Study Drug (Resting) Values are resting values after receiving study drug minus resting values before study drug (on the same day.) Stroke volume is the amount of blood pumped out of the heart (left ventricle - to the body) during each contraction. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Central Pressures After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in Heart Rate After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in Blood Pressure After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in PVR After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Pulmonary Vascular Resistance (PVR) is the resistance to flow that must be overcome to push blood through the pulmonary vasculature. Acute and chronic lung disease can both cause an increase in PVR. Chronic PVR can lead to right sided heart failure. baseline, approximately 30 minutes after study drug administration No
Secondary Change in PA Compliance After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Pulmonary artery compliance is an index of the elasticity of the blood vessel, an indication of arterial stiffness. baseline, approximately 30 minutes after study drug administration No
Secondary Change in SVR After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Systemic vascular resistance (SVR) refers to the resistance to blood flow offered by all of the systemic vasculature, excluding the pulmonary vasculature. baseline, approximately 30 minutes after study drug administration No
Secondary Change in LVSW After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Stroke work refers to the work done by the ventricle to eject a volume of blood (i.e., stroke volume) into the aorta. Ventricular stroke work can be estimated as the product of stroke volume and mean aortic pressure during ejection. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Oxygen Consumption (VO_2) After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) baseline, approximately 30 minutes after study drug administration No
Secondary Change in Arteriovenous Oxygen Difference After Study Drug (Exercise) Arteriovenous oxygen difference is the difference in the oxygen content of the blood between the arterial blood and the venous blood. It is an indication of how much oxygen is removed from the blood in capillaries as the blood circulates in the body. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Cardiac Output After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Cardiac output is equal to the stroke volume (the amount of blood pumped from a ventricle in a single heartbeat) times the heart rate. baseline, approximately 30 minutes after study drug administration No
Secondary Change in Stroke Volume After Study Drug (Exercise) Values are exercise values after receiving study drug minus exercise values before study drug (on the same day.) Stroke volume is the amount of blood pumped out of the heart (left ventricle - to the body) during each contraction. baseline, approximately 30 minutes after study drug administration No
See also
  Status Clinical Trial Phase
Withdrawn NCT01950585 - Hydroxyurea in Pulmonary Arterial Hypertension Early Phase 1
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Recruiting NCT04554160 - Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT01894035 - Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
Not yet recruiting NCT04083729 - Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy N/A
Completed NCT02821156 - Study on the Use of Inhaled NO (iNO) N/A
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Completed NCT02216279 - Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension Phase 2
Recruiting NCT01913847 - Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension Phase 3
Completed NCT06240871 - Contrast Enhanced PA Pressure Measurements
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT02377934 - Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
Recruiting NCT01091012 - Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension Phase 3
Completed NCT01463514 - Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension N/A
Completed NCT00739375 - The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension. Phase 1
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Completed NCT01484899 - Smoking: a Risk Factor for Pulmonary Arterial Hypertension? N/A